Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Part of paid clinical trials in Rochester, New York.
- Sponsor
- University of Rochester
- Study ID
- NCT07505342
- Status
- Recruiting
Conditions
- DM1
- Myotonic Dystrophy Type 1 (DM1)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 88 Years
- Healthy Volunteers
- Not accepted
Study Details
The goal of this observational study, conducted in participants' homes and requiring no travel to a study site, is to better understand disease variability in people with myotonic dystrophy type 1 (DM1) and to identify effective ways to measure symptoms. Myotonic dystrophy is one of the most variable diseases. Some people develop symptoms when they are young, others when they are much older. In the same family, some people may have mild problems, while others are strongly affected. The goal of this study is to find out more about what is causing these differences. To accomplish this, investigators will study the effects of DM1 on skeletal and smooth muscles, the heart, and the nervous system. Then, investigators will evaluate genetic differences with a blood sample. * Participants will receive a toolkit in the mail which includes all necessary equipment to participate in the study, including an iPad with video conferencing software. * Then the study team will connect with participants via videoconferencing for medical interview about DM1 symptoms and functional assessments * Participants will have their blood drawn in a lab in their community or using a home draw device, and ship it to us for research genetic analysis * Participants can chose to have their research genetic test result returned to them
Key Dates
- Start date
- May 10, 2022
- Status verified
- Mar 2026
- Primary completion
- Jan 1, 2030
- Completion
- Jan 1, 2030
Study Design
- Enrollment
- 1,000 participants (estimated)
Primary Outcome Measure
Remote assessment of grip strength [ Time Frame: 12 months ]
Central Contacts
- Jeanne Dekdebrun585-275-0420
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Rochester | Rochester | New York | 14642 | Johanna Hamel, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, NY
Related Studies
- Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)Recruiting · Virginia Commonwealth University · La Jolla, California
- Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1PHASE1/PHASE2 · Recruiting · Dyne Therapeutics · Stanford, California
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1PHASE3 · Enrolling By Invitation · Avidity Biosciences, Inc. · Los Angeles, California
- A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)PHASE1/PHASE2 · Recruiting · Vertex Pharmaceuticals Incorporated · San Carlos, California